Over 12 months, Monopar Therapeutics saw more selling than buying from its insiders — purchases of about $105,000 against sales of $5.2 million.
The largest purchase came from Vu Quan Anh (CFO), about $105,000. Notably, at least one C-suite executive was among the buyers.
Big money check: 96 institutions held MNPR as of Q2 2026, and more funds bought than sold. Looking at the quarterly pattern: Last full quarter: net selling by insiders. Insiders bought in 1 of the last 7 full quarters.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Oct 5, 2026 | STARR CHRISTOPHER M | Director | Sell | 799 | $79.67 | $64K | SEC |
| Oct 5, 2026 | STARR CHRISTOPHER M | Director | Sell | 4,631 | $78.09 | $362K | SEC |
| Oct 5, 2026 | STARR CHRISTOPHER M | Director | Sell | 2,970 | $78.82 | $234K | SEC |
| Sep 28, 2026 | Robinson Chandler | CEO | Sell | 600 | $89.79 | $54K | SEC |
| Sep 28, 2026 | Robinson Chandler | CEO | Sell | 8,368 | $88.97 | $745K | SEC |
| Sep 28, 2026 | Robinson Chandler | CEO | Sell | 9,638 | $87.96 | $848K | SEC |
| Sep 28, 2026 | Robinson Chandler | CEO | Sell | 10,450 | $87.15 | $911K | SEC |
| Aug 28, 2026 | Tsuchimoto Kim R | Director | Sell | 700 | $110.65 | $77K | SEC |
| Aug 28, 2026 | Tsuchimoto Kim R | Director | Sell | 602 | $112.93 | $68K | SEC |
| Aug 28, 2026 | Tsuchimoto Kim R | Director | Sell | 590 | $113.84 | $67K | SEC |
| Aug 28, 2026 | Tsuchimoto Kim R | Director | Sell | 615 | $109.56 | $67K | SEC |
| Aug 28, 2026 | Tsuchimoto Kim R | Director | Sell | 485 | $108.83 | $53K | SEC |
| Aug 28, 2026 | Tsuchimoto Kim R | Director | Sell | 1,098 | $111.84 | $123K | SEC |
| Aug 28, 2026 | Anderson Raymond | Director | Sell | 646 | $111.07 | $72K | SEC |
| Aug 28, 2026 | Anderson Raymond | Director | Sell | 694 | $110.04 | $76K | SEC |
In the last 12 months Monopar Therapeutics insiders made open-market purchases worth about $105,000 and sales worth about $5.2 million. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in MNPR was filed on 2026-10-05.
96 investment managers reported holding MNPR in SEC Form 13F filings for Q2 2026.
No congressional trades in MNPR were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).